ACI is a privately held biopharmaceutical company headquartered in Vancouver, BC (Canada) with operations in Prince Edward Island and West Palm Beach, Florida. ACI is focused on the development of two new therapeutic products: Alpha-1062 for the treatment of mild to moderate Alzheimer’s Disease, and Alpha-602 for the treatment of amyotrophic lateral sclerosis (ALS).
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):